Cell Impact AB

As of June 30, 2026, Cell Impact AB carries a market capitalization of 2.53M, placing it among publicly traded companies globally. Its enterprise value stands at 3.75M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Cell Impact AB's next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, Cell Impact AB has 566.94M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.90, and the price-to-book ratio stands at 0.27.

These figures are as of June 30, 2026. The EV/Sales ratio of 8.12 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 3.75M versus a market cap of 2.53M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Cell Impact AB maintains a current ratio of 1.90, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.62, indicating elevated leverage, while an interest coverage ratio of -16.80 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Cell Impact AB posted a negative return on equity (ROE) of -90.35, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -69.56, reflecting losses generated across the asset base. The company generates approximately 13,793.02 in revenue per employee across its workforce of 33.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.11 indicates how many times Cell Impact AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Cell Impact AB recorded 3,069.61 in income tax expense. The company reported a pretax loss of -11.31M and -11.32M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Cell Impact AB's stock has declined approximately 99.73% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.01.

Over the twelve months ended June 30, 2026, Cell Impact AB generated 462,066.01 in revenue and converted that into -11.32M in net income, yielding earnings per share of -0.03. EBITDA reached -4.48M, while operating income came in at -10.93M.

As of June 30, 2026, Cell Impact AB holds 38,279.79 in cash and equivalents against 1.26M in total debt, resulting in a net debt position of 467,573.24. Total book value stands at 9.22M, with working capital of 2.40M providing operational flexibility.

Cell Impact AB produced -3.14M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -143,910.36 in capital expenditures, free cash flow totaled -3.29M - equivalent to -0.01 per share.

Over the twelve months ended June 30, 2026, Cell Impact AB posted a gross margin of 0.76, reflecting its pricing power and cost economics. The operating margin of -2,365.40 and net profit margin of -2,449.14 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -182.53: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -113.23, meaning Cell Impact AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Cell Impact AB's most recent stock split took place on August 3, 2026.

As of June 30, 2026, Cell Impact AB has an Altman Z-Score of -9.72, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.